

July 11, 2022

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Glenmark Pharmaceuticals launches MINYM® GEL – India's First Topical Minocycline 4% Gel for the Treatment of Moderate to Severe Acne

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Encl: as above

Press Release

For Immediate Release

Glenmark Pharmaceuticals launches MINYM® GEL – India's First Topical Minocycline 4% Gel for the Treatment of Moderate to Severe Acne

- MINYM® Gel (Topical Minocycline 4% Gel) addresses the concerns in the treatment of acne, including the increasing resistance to currently available topical antibacterial formulations.
- MINYM can be safely used by patients above 9 years of age.

Mumbai, India; July 11, 2022: Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation-driven global pharmaceutical company, has launched India's first topical Minocycline 4% Gel for the treatment of moderate to severe acne, under the brand name MINYM®. This is a potent antibacterial gel which exerts a strong anti-inflammatory action. It also offers the lowest MIC₉₀ (minimum Inhibitory Concentration at which it stops/prevents visible growth of 90% of isolates of bacteria) compared to the available topical antibacterial formulations.

Topical antibacterial formulations are some of the commonly used class of drugs for the treatment of acne. With no new topical formulations being launched over the last 30 years, there has been a gradual increase in resistance to the currently available topical antibacterial formulationsⁱ. MINYM® Gel (Topical Minocycline 4% Gel) has been developed to address these growing concerns in treatment of acne and is safe to use in patients above 9 years of age.

Speaking at the launch, Alok Malik, Group Vice President & Head, India Formulations – Glenmark said, "Glenmark is a leader in the dermatology segment in India and has been at the forefront in providing access to the latest treatment options to the patients. We are proud to introduce the first topical Minocycline-based - MINYM® Gel, in India; proven for its potent anti-bacterial effect, anti-inflammatory action and lowest resistance, as a treatment option to patients aged 9 years and above suffering from acne."

Acne is an inflammatory skin disease affecting millions of people worldwide. It involves the pilosebaceous units and presents with comedones, papules and pustules and is affected by numerous risk factors. Acne usually begins in puberty and affects many adolescents and young adults. In a study conducted by Glenmark in 2020, on the prevalence of acne in Indiaⁱⁱⁱ, it was observed that 45 percent of the patients were males and 55 percent were females; and almost 72 percent of the patients were in the adolescent group whereas 27 percent patients were in the adult group.

-----End-----

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is ranked among the world's top 100 biopharmaceutical companies (Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world's top 50 companies in the off-patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2020, by Generics Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world's most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year in a row. For more information, visit www.glenmarkpharma.com.

Follow us on Social Media:

LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma)

For more information, please contact

Udaykumar Murthy

DGM, Corporate Communications

+91 9960377617 | corpcomm@glenmarkpharma.com

References

ⁱ Indian Journal of Dermatology, 2016, Volume 61, Issue 1, Pg 45-52

ⁱⁱ J Am Acad Dermatol. 2020 Apr;82(4):832-837

ⁱⁱⁱ https://www.researchgate.net/publication/346073719_Acne_in_Indian_population_An_epidemiological_study_evaluating_multiple_factors